About us
Suntec Medical – History
In 2005, Suntec Medical was founded in California by Dr. Pauline Lau as a drug trading company.
In 2007, Suntec established a subsidiary in Taiwan to better manage its suppliers.
In 2016, Suntec transformed into a new drug development company by in-licensing the “MINC technology”. By 2020, Suntec established several preclinical research collaborations with top medical centers including US National Institute of Health, Kyoto University, Stanford University University of Florida.
In 2021-2023, Suntec completed the filing of 14 new patent families covering various therapeutics and diagnostics for the MINC technology.
Management leadership
Suntec Medical management team are experienced leaders from Roche and Bristol-Myers Squibb, and City of Hope Cancer Center. These leaders manage business, medical, and scientific operations at various sites globally.
Suntec Medical – Management team with global experience
Director, translational medicine, Roche Palo Alto and Genentech. Biomarkers for the clinical trials of trastuzumab (Herceptin), rituximab (Rituxan), Peg-IFNα (Pegasys) and other drugs.
35 yrs experience in the pharmaceutical business & marketing. Careers in local and global marketing and medical affairs, followed by 25 years of general management in Roche and AstraZeneca in Europe, Latin America, and the US.
Expert in cancer biology, achievements in scientific affairs in biotech industry. Experience working with key opinion leaders. A university faculty and previously worked at City of Hope Medical Center.
He has 30+ years experiences in complex drug formulations including Bristol-Myers Squibb (BMS), Immunologic Pharmaceutical, TTY Biopharm, Barr Laboatories, Diatide, Inc., EnhanX, and PharmaEngine. He has developed and successfully launched liposomal formulations of Doxorubicin, Amphotericin B. and the microsphere extended-release formulation of Octreotide.
- Founder and CEO, Suntec Medical, for new immunotherapy development
- CEO, Sunyan pharmaceutical Co. Taiwan, global biopharmaceutical distribution, Latin America
- Director, Integrated Health Care, Roche Pharmaceuticals, in charge of translational medicine and precision medicine
- 30 years industrial experience
- Worked in top pharmas including BMS, Immulogic Pharmaceutical
- Developed several successfully approved drugs including Liposomal Doxorubicin and Liposomal Amphotericin B when he served as R＆D Director and Vice President at TTY Biopharm
- VP, Research and preclinical development and regulatory affairs
- Expert in cancer biology and disease signaling pathways
- 30 years in product formulation and manufacturing process improvements at Roche and Bhoeringer Mannheim
- Award winning large molecule synthesis process, Rockefeller University
- Board Certified Specialist for Pharmacology and Toxicology, Clinical Pharmacology and Internal Medicine and board member/ mentor for start-ups
- Has over 40 years of experience in life sciences, spanning R&D, Business development, marketing and sales roles (including CEO roles). Established first beta blocker to treat heart failure and a pioneer of personalized medicine at Roche
- Co-founder of successfully exited start up
- Founder and CTO, Suntec Medical, for new immunotherapy development
- CEO, Sunyan pharmaceutical Co. Taiwan, global biopharmaceutical distribution, Latin America
- Director, Integrated Health Care, Roche Pharmaceuticals, in charge of translational medicine and precision medicine
- VP, Research and preclinical development and regulatory affairs
- Expert in cancer biology and disease signaling pathways
- 30 years in product formulation and manufacturing process improvements at Roche and Bhoeringer Mannheim
- Award winning large molecule synthesis process, Rockefeller University